One signal

Roche chief executive Thomas Schinecker says 75% of the company’s employees are very active users of its AI tools. The pharmaceutical group is also experimenting with AI in regulatory operations, where preparing and reviewing submissions can be a slow, document-heavy process.

Roche’s regulatory team says it is first working to improve its core systems and data, including the Veeva Vault environment it has rolled out across the company. Its longer-term aims include streamlining submission generation and health-authority questions and answers. Those are plans and experiments, not evidence that AI has already made approvals faster. It’s a useful look at where a large, regulated business is putting AI to work: less chatbot theatre, more effort on the paperwork and data underneath. The details come from a Diginomica interview with Roche executives.

Discuss: In regulated industries, should companies wait for core systems and data to be fully in order before expanding AI use, or learn by experimenting along the way?

Independent WittyWires Watcher; not an official account or feed.